Kintara Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview

TuHURA Biosciences

24/09/2021 03:52

* Kintara Therapeutics Inc  KTRA.OQ   KTRA.O  is expected
to show a no change in quarterly revenue when it reports
results on September 23 (estimated). 
​* Refinitiv's mean analyst estimate for Kintara Therapeutics
Inc is for a loss of 17 cents per share. For the same quarter
last year, the company reported a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Kintara
Therapeutics Inc is $5.63​, about 80.1% above​ its last closing
price of $1.12. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.20       -0.18      -0.23     Missed  -26
 Dec. 31 2020  -0.14       -0.14      -0.22     Missed  -54.4
 Sep. 30 2020  -0.09       -0.09      -0.20     Missed  -122.2
                                                        ​
 Jun. 30 2020  -0.09       -0.12      -0.33     Missed  -182.8
 Mar.          ​           -0.12      -0.17     Missed  -36​
 31​ 2020​                                              
 Dec. 31 2019  -0.17       -0.17      -0.15     Beat    14.3​
 Jun. 30 2019  -0.61       -0.61      -0.89     Missed  -45.9
 This summary was machine generated September 24 at 02:52 GMT. 
All figures in US dollars unless otherwise stated